Clinical Trial Update: An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 endometrial cancer trial for recurrent or persistent disease has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Snippet

Sponsor: Xenetic Biosciences, Inc. | Conditions: Endometrial Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-06-07